Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira granted stock options and restricted stock units as hiring inducement awards under its 2014 Inducement Plan, outlining exercise price and multi‑year vesting terms.

Rhea-AI Summary

Pacira BioSciences (PCRX) granted equity inducement awards on September 2, 2026 to five new employees under its Amended and Restated 2014 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4). The awards were approved by the Board’s People & Compensation Committee without stockholder approval.

Three employees received stock options covering an aggregate 8,900 shares of common stock with a 10-year term, a four-year vesting schedule, and an exercise price of $26.58 per share, equal to the September 2, 2026 Nasdaq Global Select Market closing price. Five employees received restricted stock units for an aggregate 14,000 shares, vesting in four annual equal installments beginning September 1, 2027. All vesting is subject to continued employment and award agreements.

Key Figures

Employees receiving awards: 5 new employees Stock options: 8,900 shares Restricted stock units: 14,000 shares +4 more

Employees receiving awards

5 new employees

Inducement grants awarded September 2, 2026

Stock options

8,900 shares

Granted to 3 employees

Restricted stock units

14,000 shares

Granted to 5 employees

Option exercise price

$26.58 per share

Closing trading price on the grant date

Option term

10 years

Stock options

Option vesting schedule

4 years

25% on the first anniversary, then quarterly installments

RSU vesting schedule

4 equal installments

Annual vesting begins September 1, 2027

Key Terms

inducement awards, nasdaq listing rule 5635(c)(4), stock options, restricted stock units, +2 more

6 terms

inducement awards financial

"today announced the granting of inducement awards on September 2, 2026"

Inducement awards are special bonuses given to new employees to encourage them to join a company, often in the form of stock or money. They matter because they can motivate talented people to choose one company over another and help align their success with the company's growth. Think of it like a signing bonus to seal the deal.

nasdaq listing rule 5635(c)(4) regulatory

"In accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

stock options financial

"Three employees received stock options to purchase an aggregate of 8,900 shares"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

restricted stock units financial

"five employees received restricted stock units for an aggregate of 14,000 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

exercise price financial

"The stock options have an exercise price of $26.58 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

phase 2 medical

"PCRX-201 ... is in Phase 2 clinical development"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRISBANE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on September 2, 2026 to five new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.

Three employees received stock options to purchase an aggregate of 8,900 shares of Pacira common stock and five employees received restricted stock units for an aggregate of 14,000 shares of Pacira common stock. The stock options have a 10-year term and a four-year vesting schedule with 25 percent of the underlying shares vesting on the first anniversary of the recipient’s first day of employment and in successive equal quarterly installments over the 36 months thereafter. The stock options have an exercise price of $26.58 per share, the closing trading price of Pacira common stock on the Nasdaq Global Select Market on the date of grant. Each restricted stock unit represents the contingent right to receive one share of Pacira common stock and the restricted stock unit awards vest annually in four equal installments beginning on September 1, 2027.

Vesting of the equity awards is subject to the employee’s continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.

About Pacira

Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has two commercial-stage non-opioid treatments: EXPAREL^® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; and ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.

Investor Contact: Susan Mesco, (973) 451-4030 susan.mesco@pacira.com	Media Contact: Sara Marino, (973) 370-5430 sara.marino@pacira.com